233 related articles for article (PubMed ID: 30127498)
1. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice.
Lee SH; Moon JS; Pak BY; Kim GW; Lee W; Cho H; Kim S; Kim SJ; Oh JW
Sci Rep; 2018 Aug; 8(1):12469. PubMed ID: 30127498
[TBL] [Abstract][Full Text] [Related]
2. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
[TBL] [Abstract][Full Text] [Related]
3. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.
Kosaka K; Imamura M; Hayes CN; Abe H; Hiraga N; Yoshimi S; Murakami E; Kawaoka T; Tsuge M; Aikata H; Miki D; Ochi H; Matsui H; Kanai A; Inaba T; Chayama K
J Viral Hepat; 2015 Feb; 22(2):158-65. PubMed ID: 24943406
[TBL] [Abstract][Full Text] [Related]
4. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.
Wang C; Sun JH; O'Boyle DR; Nower P; Valera L; Roberts S; Fridell RA; Gao M
Antimicrob Agents Chemother; 2013 May; 57(5):2054-65. PubMed ID: 23403428
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing.
Bartolini B; Lionetti R; Giombini E; Sias C; Taibi C; Montalbano M; D'Offizi G; McPhee F; Hughes EA; Zhou N; Ippolito G; Garbuglia AR; Capobianchi MR
J Clin Virol; 2015 May; 66():38-43. PubMed ID: 25866334
[TBL] [Abstract][Full Text] [Related]
6. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
Wang C; Jia L; O'Boyle DR; Sun JH; Rigat K; Valera L; Nower P; Huang X; Kienzle B; Roberts S; Gao M; Fridell RA
Antimicrob Agents Chemother; 2014 Sep; 58(9):5155-63. PubMed ID: 24936600
[TBL] [Abstract][Full Text] [Related]
7. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.
Hernandez D; Zhou N; Ueland J; Monikowski A; McPhee F
J Clin Virol; 2013 May; 57(1):13-8. PubMed ID: 23384816
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
[TBL] [Abstract][Full Text] [Related]
9. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.
Hernandez D; Yu F; Huang X; Kirov S; Pant S; McPhee F
Adv Ther; 2016 Jul; 33(7):1169-79. PubMed ID: 27287851
[TBL] [Abstract][Full Text] [Related]
10. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
Teraoka Y; Uchida T; Imamura M; Hiraga N; Osawa M; Kan H; Saito Y; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
J Gen Virol; 2018 Aug; 99(8):1058-1065. PubMed ID: 29916799
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Activity of Combined NS5A Inhibitors.
O'Boyle DR; Nower PT; Gao M; Fridell R; Wang C; Hewawasam P; Lopez O; Tu Y; Meanwell NA; Belema M; Roberts SB; Cockett M; Sun JH
Antimicrob Agents Chemother; 2015 Dec; 60(3):1573-83. PubMed ID: 26711745
[TBL] [Abstract][Full Text] [Related]
12. Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
Chukkapalli V; Berger KL; Kelly SM; Thomas M; Deiters A; Randall G
Virology; 2015 Feb; 476():168-179. PubMed ID: 25546252
[TBL] [Abstract][Full Text] [Related]
13. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.
Iio E; Shimada N; Abe H; Atsukawa M; Yoshizawa K; Takaguchi K; Eguchi Y; Nomura H; Kuramitsu T; Kang JH; Matsui T; Hirashima N; Tsubota A; Kusakabe A; Hasegawa I; Miyaki T; Shinkai N; Fujiwara K; Nojiri S; Tanaka Y
J Gastroenterol; 2017 Jan; 52(1):94-103. PubMed ID: 27236547
[TBL] [Abstract][Full Text] [Related]
15. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4.
McCormick AL; Wang L; Garcia-Diaz A; Macartney MJ; Webster DP; Haque T
Antivir Ther; 2015; 20(1):81-5. PubMed ID: 24621453
[TBL] [Abstract][Full Text] [Related]
17. HCV NS5A replication complex inhibitors.
Gao M; O'Boyle DR; Roberts S
Curr Opin Pharmacol; 2016 Oct; 30():151-157. PubMed ID: 27643675
[TBL] [Abstract][Full Text] [Related]
18. A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.
Fernandes Campos GR; Ward J; Chen S; Bittar C; Vilela Rodrigues JP; Martinelli ALC; Souza FF; Pereira LRL; Rahal P; Harris M
J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33141008
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.
Plaza Z; Soriano V; Vispo E; del Mar Gonzalez M; Barreiro P; Seclén E; Poveda E
Antivir Ther; 2012; 17(5):921-6. PubMed ID: 22436385
[TBL] [Abstract][Full Text] [Related]
20. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
Yu JH; Lee JI; Lee KS; Kim JK
Virol J; 2017 Aug; 14(1):164. PubMed ID: 28836992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
